Company intelligence / Profile preview
Lijin Biomedical Technology
Suzhou, Jiangsu Sheng, Chinaknowaco.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Lijin Biomedical Technology develops innovative monoclonal and bispecific antibodies targeting cancer and immune-related indications. The company has multiple programs in preclinical through Phase II stages. Lead assets include LVGN6051 (a clinical-stage anti–4-1BB agonist) in combination with toripalimab for head and neck cancer currently in Phase II trials. Another asset includes Dalnicastobart targeting CD40.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibody (mAb)Bispecific antibody
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Lijin Biomedical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lijin Biomedical Technology.